Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer

British Journal of Cancer

Volumn 107, Issue 8, 2012, Pages 1327-1336

  Smith, G ^a   Ng, M T H ^a   Shepherd, L ^a   Herrington, C S ^a   Gourley, C ^b   Ferguson, M J ^c   Wolf, C R ^a,c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chemotherapy; Fibroblast growth factors; Ovarian cancer; Platinum drugs; Survival

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PLATINUM; PROTEIN MDM2;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CELL ASSAY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LOG RANK TEST; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84867395354     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.410     Document Type: Article

References (42)

1. Al-Hussaini M, Stockman A, Foster H, McCluggage WG (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44(2): 109-115 (Pubitemid 38296970)
2. Banerjee S, Kaye S (2011) The role of targeted therapy in ovarian cancer. Eur J Cancer 47(Suppl 3): S116-S130
3. Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, Thomssen C, Hauptmann S (2008) Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 14(1): 89-96 (Pubitemid 351377982)
4. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC (2007) Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16): 2281-2287 (Pubitemid 46954656)
5. Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59(4): 650-653 (Pubitemid 19111764)
6. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Benard J (1989) Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 49(18): 5062-5065 (Pubitemid 19239344)
7. Brown MR, Blanchette JO, Kohn EC (2000) Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 14(6): 901-918 (Pubitemid 32123680)
8. Burger RA (2011) Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 121(1): 230-238
9. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26): 2473-2483
10. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF (2001) A prognostic model for ovarian cancer. Br J Cancer 85(7): 944-952 (Pubitemid 33015994)
11. Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, Hodgkinson C, McVey R, Kitchener H, Jayson GC (2010) Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 10(5): 495-504
12. Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, ER Siegel, Schwartz PE, Rutherford TJ, Santin AD (2010) Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Am J Obstet Gynecol 203(2): 162 e1-162
13. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP, Ferrara N (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23(14): 2800-2810 (Pubitemid 39013552)
14. Fujimoto J, Ichigo S, Hori M, Hirose R, Sakaguchi H, Tamaya T (1997) Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. Eur J Gynaecol Oncol 18(5): 349-352 (Pubitemid 27437741)
15. Garrett CR, Eng C (2011) Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 11(7): 937-949
16. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K (1993) Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53(19): 4550-4554 (Pubitemid 23304378)
17. Kalamanathan S, Bates V, Lord R, Green JA (2011) The mutational profile of sporadic epithelial ovarian carcinoma. Anticancer Res 31(8): 2661-2668
18. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12): e232
19. Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D (2011) Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One 6(3): e18202
20. Kristensen GB, Trope C (1997) Epithelial ovarian carcinoma. Lancet 349(9045): 113-117 (Pubitemid 127700347)
21. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC, Smyth JF (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48(21): 6166-6172 (Pubitemid 18266818)
22. Ledermann JA, Raja FA (2010) Targeted trials in ovarian cancer. Gynecol Oncol 119(1): 151-156
23. Lee KR, Young RH (2003) The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 27(3): 281-292 (Pubitemid 36245793)
24. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211(1): 26-35 (Pubitemid 46092026)
25. Lu Y, Han J, Scanlon KJ (1988) Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J Biol Chem 263(10): 4891-4894
26. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139 (Pubitemid 38637993)
27. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD (2006) Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25(14): 2060-2069
28. Mi RR, Ni H (2003) MDM2 sensitizes a human ovarian cancer cell line. Gynecol Oncol 90(2): 238-244 (Pubitemid 36952009)
29. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63 (Pubitemid 14203433)
30. Ohishi Y, Oda Y, Uchiumi T, Kobayashi H, Hirakawa T, Miyamoto S, Kinukawa N, Nakano H, Kuwano M, Tsuneyoshi M (2002) ATPbinding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8(12): 3767-3775 (Pubitemid 35424768)
31. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS (2008) Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 7(10): 3247-3255
32. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26): 2484-2496
33. Pliarchopoulou K, Pectasides D (2011) Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol 79(1): 17-23
34. Prakash J, de Jong E, Post E, Gouw AS, Beljaars L, Poelstra K (2010) A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J Control Release 145(2): 91-101
35. Scottish Intercollegiate Guidelines Network Epithelial Ovarian Cancer: A National Clinical Guideline (2003) ISBN 1 899893 93 8
36. Smith G, Dawe RS, Clark C, Evans AT, Comrie MM, Wolf CR, Ferguson J, Ibbotson SH (2003a) Quantitative real-time reverse transcriptionpolymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. J Invest Dermatol 121(2): 390-398 (Pubitemid 36969914)
37. Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, Ibbotson SH (2003b) Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361(9366): 1336-1343 (Pubitemid 36514866)
38. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16): 5198-5208
39. Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22(47): 7369-7375
40. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2): 116-129
41. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas N Engl J Med 363(16): 1532-1543
42. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11(18): 6422-6430 (Pubitemid 41338978)